The Thrombophilia drugs in development market research report provides comprehensive information on the therapeutics under development for Thrombophilia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thrombophilia. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Thrombophilia - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thrombophilia and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Thrombophilia by ten companies/universities/institutes. The top development phase for Thrombophilia is preclinical with six drugs in that stage. The Thrombophilia pipeline has seven drugs in development by companies and three by universities/ institutes. Some of the companies in the Thrombophilia pipeline products market are: Johnson & Johnson, University College London and Akari Therapeutics.

The key targets in the Thrombophilia pipeline products market include Beta 2 Glycoprotein 1 (APC Inhibitor or Activated Protein C Binding Protein or Anticardiolipin Cofactor or Apolipoprotein H or APOH), ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2′ Phospho ADP Ribosyl Cyclase/2′ Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC or EC, and Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5).

The key mechanisms of action in the Thrombophilia pipeline product include Vitamin K Epoxide Reductase (Warfarin Sensitive) (EC Inhibitor with one drug in Discovery. The Thrombophilia pipeline products include seven routes of administration with the top ROA being Subcutaneous and five key molecule types in the Thrombophilia pipeline products market including Monoclonal Antibody, and Small Molecule.

Thrombophilia overview

Thrombophilia is a condition where the blood clots too easily. It increases risk of deep vein thrombosis (DVT), a blood clot in a vein, usually the leg, and pulmonary embolism (PE), a clot in the lungs. The most common inherited form of thrombophilia is Factor V Leiden thrombophilia. It is caused by genetic problem with a protein responsible for clotting. Duplex ultrasonography is an imaging test that uses sound waves to look at the flow of blood in the veins and can help with diagnosis. Anticoagulants, compression stockings, andn intravenous unfractionated heparin can be used for the treatment.

For a complete picture of Thrombophilia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.